Epilepsy is a chronic neurologic disorder that affects over 70 million people worldwide.
Despite the availability of over 20 antiseizure drugs (ASDs) for symptomatic treatment of …

Epilepsy is a disease characterized by abnormal brain activity and a predisposition to
generate epileptic seizures, leading to neurobiological, cognitive, psychological, social, and …

Importance Fenfluramine treatment may reduce monthly convulsive seizure frequency in
patients with Dravet syndrome who have poor seizure control with their current stiripentol …

The therapeutic potential of cannabidiol (CBD) in seizure disorders has been known for
many years, but it is only in the last decade that major progress has been made in …

Maintaining average activity within a set-point range constitutes a fundamental property of
central neural circuits. However, whether and how activity set points are regulated remains …

Dravet syndrome (DS), also known as severe myoclonic epilepsy of infancy (SMEI), is one of
the rare early childhood intractable epileptic encephalopathies associated with pleomorphic …

Normal brain function requires a tightly regulated balance between excitatory and inhibitory
neurotransmissions. γ‐Aminobutyric acid type A (GABAA) receptors represent the major …

Highly purified cannabidiol (CBD) has demonstrated efficacy with an acceptable safety
profile in patients with Lennox‐Gastaut syndrome or Dravet syndrome in randomized …

Despite significant progress in unraveling the genetic causes of neurodevelopmental
disorders (NDDs), a substantial proportion of individuals with NDDs remain without a …

There remains an urgent need for new therapies for treatment-resistant epilepsy. Sodium
channel blockers are effective for seizure control in common forms of epilepsy, but loss of …